Allergan Buy Strengthens Undervalued Pfizer’s Moat
November 23, 2015 at 11:00 AM EST
The pharma megadeal strategically strengthens Pfizer with a lower tax rate and an increased growth profile, writes Morningstar’s Damien Conover.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.